BioSpace News Archive

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the Chardan 4 th Annual Genetic Medicines Conference on Mon., Oct. 5

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company’s Chief Executive Officer, will present at the H.C. Wainwright 4 th Annual NASH Investor Conference on Monday, October 5, 2020 at 11:30 AM ET. The live and archived webcast of the presentation wi

LabCorp (NYSE: LH) will release its third quarter of 2020 financial results before the market opens on Tuesday, Oct. 27, 2020, and then will host a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results. The earnings release and accompanying financial information will be posted on the LabCorp Investor Relations website . Interested parties can access the conference call by dialing 1-

Messer’s robust bulk medical oxygen supply network maintained continual supply to NYC hospitals during the pandemic as demand skyrocketed

Shape Therapeutics, Inc. (ShapeTX), a pre-clinical stage company with an industry-leading RNA targeting technology platform, announced today that Francois Vigneault, PhD., President & Chief Executive Officer, will highlight advances in their RNAfix™ ADAR editing platform, including data that demonstrates RNA editing up to ~90% in genes implicated in Parkinson’s disease. The presentation will be on Friday, October 2, 2020 at

Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ ® (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were app

Junshi Biosciences announced that an Independent Monitoring Committee determined that the randomized, double-blind, placebo-controlled, international multi-center Phase III study JUPITER-02 at the interim analysis had met its pre-specified primary endpoint.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement supporting the Administration’s plans to provide COVID-19 rapid tests to school children. “Quidel Corporation welcomes President Trump’s announcement that the Administration will direct millions of Abbott’s visually read antigen t

Physicians’ Education Resource® LLC (PER®), a leading resource for continuing medical education, proudly announces it will present the International Society of Gastrointestinal Oncology® (ISGIO) 17th Annual 2020 Gastrointestinal Oncology Conference, as a two-day continuing medical education (CME)-certified virtual, interactive meeting Oct. 2-3.

CHOP and 38 other health systems in 45 states and Washington, DC have committed to addressing racism and the public health disparities caused by racism